Han ZQ, Wen LN. Tofacitinib for ulcerative colitis: A promising treatment option. World J Gastroenterol 2024; 30(40): 4386-4392 [PMID: PMC11525864 DOI: 10.3748/wjg.v30.i40.4386]
Corresponding Author of This Article
Li-Na Wen, Doctor, Research Associate, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian Street, Haidian District, Beijing 100038, China. wenlina3074@bjsjth.cn
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 28, 2024; 30(40): 4386-4392 Published online Oct 28, 2024. doi: 10.3748/wjg.v30.i40.4386
Tofacitinib for ulcerative colitis: A promising treatment option
Zong-Qiang Han, Li-Na Wen
Zong-Qiang Han, Department of Laboratory Medicine, Beijing Xiaotangshan Hospital, Beijing 102211, China
Li-Na Wen, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Author contributions: Wen LN designed research; Han ZQ and Wen LN performed research, analyzed data; Han ZQ wrote the letter; Wen LN revised the letter.
Supported byThe Scientific Research Cultivation Fund of Capital Medical University, No. PYZ23175.
Conflict-of-interest statement: The two authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Na Wen, Doctor, Research Associate, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian Street, Haidian District, Beijing 100038, China. wenlina3074@bjsjth.cn
Received: July 28, 2024 Revised: September 21, 2024 Accepted: September 26, 2024 Published online: October 28, 2024 Processing time: 79 Days and 23.1 Hours
Abstract
A single center retrospective clinical study revealed the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC). This study has clinical reference value but also has some limitations. Previous studies, including this clinical trial, have shown that tofacitinib could be a promising treatment option for UC, but further clinical research is required to prove this point.
Core Tip: Tofacitinib can effectively alleviate ulcerative colitis (UC) without being affected by previous tumor necrosis factor antibody therapy. UC may recur after discontinuation of medication, but symptoms will be relieved after resuming tofacitinib administration. While demonstrating effectiveness, tofacitinib has adverse reactions such as herpes zoster and inflammatory reactions. These findings provide doctors with a reference for treating UC in clinical practice. However, more prospective cohort study data are still needed to provide more accurate evidence for the clinical application and safety of tofacitinib.
